The team's study, published in Cancer Cell, shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by ...

Previous research suggests that platelet-derived growth factor receptor alpha (PDGFRA) appears to play a multifaceted role in the pathogenesis of both adult and pediatric high-grade gliomas.

A study, published in Cancer Cell, shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United ...

Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) plays a role at multiple levels in the development of high-grade gliomas and represents a promising therapeutic target. Previous attempts to ...

Avapritinib is a small molecule that crosses the blood-brain-barrier and targets platelet derived growth factor alpha (PDGFRA), which is overactive in some pediatric high-grade gliomas and leads ...

We were excited to see that avapritinib essentially shut off PDGFRA signaling in mouse brain tumors." Carl Koschmann, M.D., ChadTough Defeat DIPG Research Professor and clinical scientific ...

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever ...

More information: Soniya Bastola et al, Endothelial-secreted Endocan activates PDGFRA and regulates vascularity and spatial ...

Avapritnib has been approved to treat advanced systemic mastocytosis and indolent systemic mastocytosis and gastrointestinal stromal tumors with a platelet-derived growth factor receptor alpha (PDGFRA ...

Non-KIT exon 11 mutations and wild-type KIT/PDGFRA GISTs show less favorable responses, suggesting earlier surgery if response is insufficient. Mutation testing is crucial for guiding treatment ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...